comprehensive -WSS

comprehensive

author：focus 2025-09-29 01:36:31 - browse：65

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Wikipedia

WSS

Study suggests new cause of Down syndrome: cells linked to aging

Scientists successfully use ultrasound imaging to map brain activity

Startling documents reveal new facets of Sacklers' opioid empire

Health insurers say they are turning to AI to cut costs, improve care

Childbirth

At JPM 2024, hospital systems pitch financial strength to investors

entertainment

comprehensive

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Cancer drug shortages should be causing more outrage

Male doctors called my cancer incurable. A female doctor showed it wasn't

Trump demands the U.S. pay no more for drugs than other countries … again

Dark money group runs ads on China biotech bill

Drug repurposing or repositioning? The language matters

Physician assistants need a new name. Here's what it should be

DIEP, the 'gold standard' of breast reconstruction, is under threat

David Sabatini, ex

focus

Prosthetic arm enables patients to feel the objects they grip

Startling documents reveal new facets of Sacklers' opioid empire

Stigma and the return of syphilis

iTeos Therapeutics debuts first data on TIGIT

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Biohaven protein

hotspot

focus

Wikipedia

explore